Bioxytran (BIXT) Gross Profit Growth (1y) (2011 - 2018)
Bioxytran (BIXT) Gross Profit Growth (1y) (2011 - 2018) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 11.24% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 15.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 63.51% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 126.09% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 33.01% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 57.16% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -99.98% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 351.57% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | -39.26% |
| Mar 31, 2018 | 69.01% |
| Dec 31, 2017 | -118.46% |
| Sep 30, 2017 | 27.25% |
| Jun 30, 2017 | -45.45% |
| Mar 31, 2017 | -142.37% |
| Dec 31, 2016 | 844.09% |
| Sep 30, 2016 | 46.41% |
| Jun 30, 2016 | -17.63% |
| Mar 31, 2016 | -69.30% |
| Dec 31, 2015 | 93.81% |
| Sep 30, 2015 | 497.97% |
| Jun 30, 2015 | 72.87% |
| Mar 31, 2015 | -68.90% |
| Dec 31, 2014 | -212.09% |
| Sep 30, 2014 | -50.46% |
| Jun 30, 2014 | -53.25% |
| Mar 31, 2014 | 48.35% |
| Dec 31, 2013 | 7.79% |
| Sep 30, 2013 | 140.86% |